{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:11:47Z","timestamp":1789773107282,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018806","name":"Department of Science and Technology of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.intimp.2024.112535","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T17:01:23Z","timestamp":1718989283000},"page":"112535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A joint population pharmacokinetic model to assess the high variability of whole-blood and intracellular tacrolimus in early adult renal transplant recipients"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4219-5953","authenticated-orcid":false,"given":"Junjun","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3630-9002","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112535_b0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.intimp.2024.112535_b0010","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2024.112535_b0015","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1056-8719(02)00158-2","article-title":"Validation of methods to study the distribution and protein binding of tacrolimus in human blood","volume":"46","author":"Zahir","year":"2001","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.intimp.2024.112535_b0025","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/bcp.13083","article-title":"Comparative performance of oral midazolam clearance and plasma 4beta-hydroxycholesterol to explain interindividual variability in tacrolimus clearance","volume":"82","author":"Vanhove","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2125.2003.02008.x","article-title":"Factors affecting variability in distribution of tacrolimus in liver transplant recipients","volume":"57","author":"Zahir","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0035","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00007691-200410000-00008","article-title":"Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation","volume":"26","author":"Zahir","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.intimp.2024.112535_b0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","article-title":"The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein","volume":"40","author":"Zhang","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0045","first-page":"633","article-title":"The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects","volume":"27","author":"Moller","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.intimp.2024.112535_b0050","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","article-title":"Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review","volume":"59","author":"Kirubakaran","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0055","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bcp.12830","article-title":"External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients","volume":"81","author":"Zhao","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0060","article-title":"Clinical pharmacokinetics and impact of hematocrit on monitoring and dosing of tacrolimus early after heart and lung transplantation","author":"Sikma","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0065","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/TP.0000000000002052","article-title":"High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes","volume":"102","author":"Rayar","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2024.112535_b0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1034\/j.1399-3046.2001.005002075.x","article-title":"Tacrolimus and diarrhea: pathogenesis of altered metabolism","volume":"5","author":"Mittal","year":"2001","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.intimp.2024.112535_b0075","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bcp.12361","article-title":"Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling","volume":"78","author":"St\u00f8rset","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0080","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0085","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1345\/aph.1K628","article-title":"Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?","volume":"42","author":"Lam","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.intimp.2024.112535_b0090","first-page":"1093","article-title":"Wuzhi capsule dosage affects tacrolimus elimination in adult kidney transplant recipients, as determined by a population pharmacokinetics analysis","volume":"14","author":"Chen","year":"2021","journal-title":"Pharmacogenom. Pers. Med."},{"key":"10.1016\/j.intimp.2024.112535_b0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/FTD.0b013e31829da6dd","article-title":"Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients","volume":"36","author":"Elens","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.intimp.2024.112535_b0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00228-014-1656-3","article-title":"The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients","volume":"70","author":"Lunde","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.112535_b0115","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.phrs.2016.07.027","article-title":"Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation?","volume":"111","author":"Capron","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2024.112535_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.733285","article-title":"Monitoring intra-cellular tacrolimus concentrations in solid organ transplantation: use of peripheral blood mononuclear cells and graft biopsy tissue","volume":"12","author":"Sallustio","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0125","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/TP.0000000000004287","article-title":"P-glycoprotein, FK-binding Protein-12, and the intracellular tacrolimus concentration in T-lymphocytes and monocytes of kidney transplant recipients","volume":"107","author":"Udomkarnjananun","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2024.112535_b0130","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-021-03215-9","article-title":"The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients","author":"Wang","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0135","doi-asserted-by":"crossref","first-page":"e0153491","DOI":"10.1371\/journal.pone.0153491","article-title":"Monitoring the intracellular tacrolimus concentration in kidney transplant recipients with stable graft function","volume":"11","author":"Han","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.112535_b0140","unstructured":"Viva-E System Gold-standard drug-testing performance with EMIT technology Siemens Global Website. Available from: http:\/\/www.healthcaresiemenscom\/drug-testing-diagnostics\/viva-drug-testing\/viva-e-drug-testing-system (last accessed June 25 2015) 2014."},{"key":"10.1016\/j.intimp.2024.112535_b0145","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jpba.2010.06.022","article-title":"Evaluation of the architect tacrolimus assay in kidney, liver, and heart transplant recipients","volume":"53","author":"Bazin","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.intimp.2024.112535_b0150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cca.2011.12.003","article-title":"The association of the UGT1A8, SLCO1B3 and ABCC2\/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals","volume":"413","author":"Geng","year":"2012","journal-title":"Clin. Chim. Acta; Int. J. Clin. Chem."},{"key":"10.1016\/j.intimp.2024.112535_b0155","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation Workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0160","unstructured":"S.L. Beal, L.B. Sheiner, A. Boeckmann, R.J. Bauer. NONMEM User's Guides. Ellicott City, MD, USA: Icon Development Solutions (1989)."},{"key":"10.1016\/j.intimp.2024.112535_b0165","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s13318-022-00767-8","article-title":"A population pharmacokinetic model of whole-blood and intracellular tacrolimus in kidney transplant recipients","volume":"47","author":"Franken","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0170","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","article-title":"The importance of modeling interoccasion variability in population pharmacokinetic analyses","volume":"21","author":"Karlsson","year":"1993","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.intimp.2024.112535_b0175","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A general model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.intimp.2024.112535_b0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic basis of using body size and maturation to predict clearance in humans","volume":"24","author":"Anderson","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0185","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0190","unstructured":"W. Jusko, R. D'Ambrosio. Monitoring FK 506 concentrations in plasma and whole blood. Transplant P 1991; 23: 2732-5."},{"key":"10.1016\/j.intimp.2024.112535_b0195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.112535_b0200","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/mol.58.2.361","article-title":"Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators","volume":"58","author":"Pascussi","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0205","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1046\/j.0014-2956.2001.02540.x","article-title":"Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor","volume":"268","author":"Pascussi","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.intimp.2024.112535_b0210","doi-asserted-by":"crossref","unstructured":"J.S. Owen, J. Fiedler-Kelly. Introduction to population pharmacokinetic\/pharmacodynamic analysis with nonlinear mixed effects models. 2014.","DOI":"10.1002\/9781118784860"},{"key":"10.1016\/j.intimp.2024.112535_b0215","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.intimp.2024.112535_b0220","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270003253624","article-title":"Model appropriateness and population pharmacokinetic modeling","volume":"43","author":"Ette","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0225","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0230","first-page":"327","article-title":"Guidelines for immunosuppressive therapy in Chinese renal transplant recipients","volume":"7","author":"Shi","year":"2016","journal-title":"Organ Transplantation"},{"key":"10.1016\/j.intimp.2024.112535_b0235","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/bcp.14585","article-title":"Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients","volume":"87","author":"Francke","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0240","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4416","article-title":"Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry","volume":"33","author":"Bahmany","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.intimp.2024.112535_b0245","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cca.2019.11.033","article-title":"Validation and evaluation of four sample preparation methods for the quantification of intracellular tacrolimus in peripheral blood mononuclear cells by UHPLC-MS\/MS","volume":"503","author":"van Merendonk","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.intimp.2024.112535_b0250","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jpba.2018.01.002","article-title":"UPLC-MS\/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4+ and B CD19+ lymphocytes","volume":"152","author":"Romano","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.intimp.2024.112535_b0255","doi-asserted-by":"crossref","first-page":"e4416","DOI":"10.1002\/bmc.4416","article-title":"Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry","volume":"33","author":"Bahmany","year":"2019","journal-title":"Biomed. Chromatogr. : BMC"},{"key":"10.1016\/j.intimp.2024.112535_b0260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/clpt.1989.7","article-title":"Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism","volume":"45","author":"Awni","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.112535_b0265","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1432-2277.2012.01513.x","article-title":"Anemia and erythrocytosis in patients after kidney transplantation","volume":"25","author":"Malyszko","year":"2012","journal-title":"Transplant Int. Official J. European Soc. Organ Transplant."},{"key":"10.1016\/j.intimp.2024.112535_b0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"Storset","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.112535_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.717148","article-title":"Case Report: Low Hematocrit Leading to Tacrolimus Toxicity","volume":"12","author":"Piletta-Zanin","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0285","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40262-019-00854-1","article-title":"Unbound plasma, total plasma, and whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation","volume":"59","author":"Sikma","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.intimp.2024.112535_b0290","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/TP.0000000000004287","article-title":"P-glycoprotein, FK-binding protein-12, and the Intracellular tacrolimus concentration in T-lymphocytes and monocytes of kidney transplant recipients","volume":"107","author":"Udomkarnjananun","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2024.112535_b0295","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fphar.2017.00358","article-title":"Tacrolimus updated guidelines through popPK Modeling: how to benefit more from CYP3A Pre-emptive genotyping prior to kidney transplantation","volume":"8","author":"Woillard","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112535_b0300","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40262-016-0491-3","article-title":"A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach","volume":"56","author":"Andreu","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0305","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jcpt.12599","article-title":"Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients","volume":"42","author":"Chen","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.intimp.2024.112535_b0310","doi-asserted-by":"crossref","first-page":"728","DOI":"10.5414\/CP202152","article-title":"The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients","volume":"53","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.112535_b0315","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5414\/CP202226","article-title":"Tacrolimus therapy causes hepatotoxicity in patients with a history of liver disease","volume":"53","author":"Ko","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2024.112535_b0320","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1124\/dmd.117.076737","article-title":"Wuzhi tablet (schisandra sphenanthera extract) is a promising tacrolimus-sparing agent for renal transplant recipients who are CYP3A5 Expressers: a two-phase prospective study","volume":"45","author":"Li","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.intimp.2024.112535_b0325","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13318-020-00609-5","article-title":"Population pharmacokinetic analysis of tacrolimus in adult chinese patients with myasthenia gravis: a prospective study","volume":"45","author":"Liu","year":"2020","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.intimp.2024.112535_b0330","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-021-03114-9","article-title":"Factors affecting time-varying clearance of cyclosporine in adult renal transplant recipients: a population pharmacokinetic perspective","author":"Mao","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.intimp.2024.112535_b0335","doi-asserted-by":"crossref","first-page":"e0230195","DOI":"10.1371\/journal.pone.0230195","article-title":"Pharmacogenetic-Whole blood and intracellular pharmacokinetic-Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients","volume":"15","author":"Tron","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.112535_b0340","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/FTD.0000000000000982","article-title":"Association Between the Intracellular Tacrolimus Concentration in CD3 + T Lymphocytes and CD14 + Monocytes and Acute Kidney Transplant Rejection","volume":"44","author":"Udomkarnjananun","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.intimp.2024.112535_b0345","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2008.01.007","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research","volume":"29","author":"Danhof","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2024.112535_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105471","article-title":"Incorporating nonlinear kinetics to improve predictive performance of population pharmacokinetic models for ciclosporin in adult renal transplant recipients: A comparison of modelling strategies","volume":"153","author":"Mao","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2024.112535_b0355","doi-asserted-by":"crossref","first-page":"1016399","DOI":"10.3389\/fphar.2022.1016399","article-title":"Applying machine learning to the pharmacokinetic modeling of cyclosporine in adult renal transplant recipients: a multi-method comparison","volume":"13","author":"Mao","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T15:39:15Z","timestamp":1720280355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924010567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":71,"alternative-id":["S1567576924010567"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112535","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A joint population pharmacokinetic model to assess the high variability of whole-blood and intracellular tacrolimus in early adult renal transplant recipients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112535"}}